标题
Melphalan Flufenamide (Melflufen): First Approval
作者
关键词
-
出版物
DRUGS
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-05-07
DOI
10.1007/s40265-021-01522-0
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long‐term survival follow‐up from the Phase II study O‐12‐M1
- (2021) Sara Bringhen et al. BRITISH JOURNAL OF HAEMATOLOGY
- Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen
- (2021) Juho J. Miettinen et al. Cancers
- OCEAN: a randomized Phase III study of melphalan flufenamide + dexamethasone to treat relapsed refractory multiple myeloma
- (2020) Fredrik Schjesvold et al. Future Oncology
- Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1–2 study
- (2020) Paul G Richardson et al. Lancet Haematology
- Melflufen, a peptide‐conjugated alkylator, is an efficient anti‐neo‐plastic drug in breast cancer cell lines
- (2020) Alexander Schepsky et al. Cancer Medicine
- Melflufen: A Peptide–Drug Conjugate for the Treatment of Multiple Myeloma
- (2020) María-Victoria Mateos et al. Journal of Clinical Medicine
- Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma
- (2020) Paul G. Richardson et al. JOURNAL OF CLINICAL ONCOLOGY
- OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis
- (2019) Giovanni Palladini et al. BLOOD
- Melflufen - a peptidase-potentiated alkylating agent in clinical trials
- (2017) Malin Wickström et al. Oncotarget
- In vitro and in vivo activity of melflufen (J1) in lymphoma
- (2016) Maryam Delforoush et al. BMC CANCER
- In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia
- (2016) Sara Strese et al. Oncotarget
- First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies
- (2015) Åke Berglund et al. INVESTIGATIONAL NEW DRUGS
- Positioning of aminopeptidase inhibitors in next generation cancer therapy
- (2014) Sarina M. Hitzerd et al. AMINO ACIDS
- In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells
- (2013) D. Chauhan et al. CLINICAL CANCER RESEARCH
- The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan
- (2010) Malin Wickström et al. BIOCHEMICAL PHARMACOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started